益豐藥房(603939.SH):就申請發行可轉債、上交所暫緩審議
格隆匯8月4日丨益豐藥房(603939.SH)公佈,上海證券交易所(“上交所”)上市審核委員會於2023年8月3日召開2023年第69次審議會議,對公司向不特定對象發行可轉換公司債券的申請進行了審核。會議審議結果為暫緩審議,並提出了需進一步落實事項:
請發行人進一步説明國家醫療保障局官網曝光台發佈的“2023年第二期曝光典型案例(十例)”中“湖南省湘西州益豐大藥房連鎖股份有限公司吉首人民北路分店違法違規使用醫保基金案”是否構成發行人重大違法行為。請保薦人和發行人律師發表明確核查意見。
公司將與相關中介機構對上述事項進行落實及回覆。公司本次向不特定對象發行可轉換公司債券事項尚需通過上交所審核,並獲得中國證監會註冊後方可實施。最終能否通過上交所審核並經中國證監會註冊通過及其時間尚存在不確定性。公司將根據該事項的審核進展情況,及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.